

## Remepy

**Dr. Michal Tsur, co-founder and co-CEO**

### **Overview for Biomed May 2025**

Many diseases are better treated by combining drugs with non-pharmacological interventions. Remepy's vision is to make such combinations standardized, accessible and personalized at scale with our Hybrid Drugs™.

**Remepy is bringing to market a novel line of Hybrid Drugs™, that combine traditional drugs with therapeutic software integrating unique adaptive multi-modality digital protocols. Hybrid Drugs are regulated either as an SaMD-Drug combination, or via FDA's new PDURs framework, that facilitates claims based on software output as part of a drug label.**

With each hybrid drug prescription, patients receive access to a dedicated therapeutic app, with interventions tailored to the drug treatment. The interventions include motor, cognitive, psychological, and behavioral interventions that trigger MOAs that are synergistic with each drug. The app provides an AI driven digital treatment protocol with daily interventions. The app also checks-in with the patient frequently and adapts treatment based on patient feedback, activity, and progress.

Remepy's is commercializing its Hybrid Drugs, its digital interventions and digital treatment protocols, through partnerships with pharma.

Clinical:

1. Remepy conducted 3 monotherapy controlled studies, in a total of 183 human subjects. Subjects were assessed using fMRI, blood samples and psychological, cognitive and motor assessment. Studies showed significant improvement in neuroplasticity, levels of pro-inflammatory cytokines, and psychological and cognitive measures. High level fascinating data will be shared as part of presentation.

2. Remepy recently completed a double blind, placebo controlled, randomized study, using Hybridopa, a first of its kind Hybrid Drug for PD, meeting its primary endpoint. Study showed that Hybridopa significantly Improved UPDRS parts 2+3, as well as increased connectivity in thalamo-cortical circuit. High level data from the Remepy's Butterfly study will be shared at Biomed.
3. Remepy will be launching during H1 2026 its phase III trial for Hybridopa: An innovative Hybrid Drug for Parkinson's Disease.

**Business:**

1. Remepy is focused on partnership with pharma for commercialization of Hybridopa upon successful phase 3.
2. Remepy is focused on partnership with pharma to bring to market additional hybrid drugs building on its monotherapy data validating its effects on motor, cognitive, psychological and immune symptoms.